iSpecimen Inc. Accounts Receivable, Credit Loss Expense (Reversal)
iSpecimen Inc. (ISPC) reported Accounts Receivable, Credit Loss Expense (Reversal) of -$3.58 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ProvisionForDoubtfulAccounts · last filed 2026-08-14
- iSpecimen Inc. accounts receivable, credit loss expense (reversal) for the quarter ending 2026-06-30 was -$3.95K.
- iSpecimen Inc. accounts receivable, credit loss expense (reversal) for the quarter ending 2026-03-31 was $368.00, a 99.67% decline year-over-year.
- iSpecimen Inc. accounts receivable, credit loss expense (reversal) for the quarter ending 2025-12-31 was $45.81K, a 90.84% decline year-over-year.
- iSpecimen Inc. accounts receivable, credit loss expense (reversal) for the quarter ending 2025-09-30 was -$3.52K, a 380.78% decline year-over-year.
- iSpecimen Inc. accounts receivable, credit loss expense (reversal) for fiscal 2025 was $59.86K, a 91.52% decline from fiscal 2024.
- iSpecimen Inc. accounts receivable, credit loss expense (reversal) for fiscal 2024 was $705.72K, a 131.36% increase from fiscal 2023.
- iSpecimen Inc. accounts receivable, credit loss expense (reversal) for fiscal 2023 was $305.04K, a 186.20% increase from fiscal 2022.
- iSpecimen Inc. accounts receivable, credit loss expense (reversal) for fiscal 2022 was $106.58K, a 33.83% decline from fiscal 2021.
| Period end | Accounts Receivable, Credit Loss Expense (Reversal) 3 month | Accounts Receivable, Credit Loss Expense (Reversal) 6 month | Accounts Receivable, Credit Loss Expense (Reversal) 9 month | Accounts Receivable, Credit Loss Expense (Reversal) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$3.95K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$3.58K 10-Q · filed 2026-08-14 | $42.23K derived: sum of 3 quarters · filed 2026-08-14 | $38.71K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $368.00 10-Q · filed 2026-05-18 | $46.17K derived: sum of 2 quarters · filed 2026-05-18 | $42.65K derived: sum of 3 quarters · filed 2026-05-18 | -$50.81K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $45.81K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01 | $42.28K derived: sum of 2 quarters · filed 2026-04-01 | -$51.18K derived: sum of 3 quarters · filed 2026-08-14 | $59.86K 10-K · filed 2026-04-01 |
| 2025-09-30 | -$3.52K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-17 | -$96.98K derived: sum of 2 quarters · filed 2026-08-14 | $14.06K 10-Q · filed 2025-11-17 | $514.02K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$93.46K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $17.58K 10-Q · filed 2026-08-14 | $517.54K derived: sum of 3 quarters · filed 2026-08-14 | $518.79K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $111.04K 10-Q · filed 2026-05-18 | $611.00K derived: sum of 2 quarters · filed 2026-05-18 | $612.25K derived: sum of 3 quarters · filed 2026-05-18 | $618.84K derived: sum of 4 quarters · filed 2026-05-18 |
| 2024-12-31 | $499.96K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01 | $501.21K derived: sum of 2 quarters · filed 2026-04-01 | $507.80K derived: sum of 3 quarters · filed 2026-04-01 | $705.72K 10-K · filed 2026-04-01 |
| 2024-09-30 | $1.25K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-17 | $7.84K derived: sum of 2 quarters · filed 2025-11-17 | $205.76K 10-Q · filed 2025-11-17 | $267.75K derived: sum of 4 quarters · filed 2025-11-17 |
| 2024-06-30 | $6.59K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $204.51K 10-Q · filed 2025-08-14 | $266.50K derived: sum of 3 quarters · filed 2025-08-14 | $247.94K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $197.92K 10-Q · filed 2025-05-19 | $259.91K derived: sum of 2 quarters · filed 2025-05-19 | $241.35K derived: sum of 3 quarters · filed 2025-05-19 | $350.17K derived: sum of 4 quarters · filed 2025-05-19 |
| 2023-12-31 | $61.99K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-14 | $43.43K derived: sum of 2 quarters · filed 2025-04-14 | $152.25K derived: sum of 3 quarters · filed 2025-04-14 | $305.04K 10-K · filed 2025-04-14 |
| 2023-09-30 | -$18.56K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $90.26K derived: sum of 2 quarters · filed 2024-11-07 | $243.05K 10-Q · filed 2024-11-07 | $8.78K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $108.82K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $261.61K 10-Q · filed 2024-08-06 | $27.33K derived: sum of 3 quarters · filed 2024-08-06 | $98.55K derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $152.79K 10-Q · filed 2024-05-07 | -$81.49K derived: sum of 2 quarters · filed 2024-05-07 | -$10.27K derived: sum of 3 quarters · filed 2024-05-07 | $94.27K derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$234.28K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | -$163.06K derived: sum of 2 quarters · filed 2024-03-13 | -$58.52K derived: sum of 3 quarters · filed 2024-03-13 | $106.58K 10-K · filed 2024-03-13 |
| 2022-09-30 | $71.21K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $175.76K derived: sum of 2 quarters · filed 2023-11-02 | $340.86K 10-Q · filed 2023-11-02 | $468.08K derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $104.55K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $269.64K 10-Q · filed 2023-08-02 | $396.86K derived: sum of 3 quarters · filed 2023-08-02 | $391.10K derived: sum of 4 quarters · filed 2023-08-02 |
| 2022-03-31 | $165.10K 10-Q · filed 2023-05-04 | $292.31K derived: sum of 2 quarters · filed 2023-05-04 | $286.55K derived: sum of 3 quarters · filed 2023-05-04 | $305.52K derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $127.22K derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-30 | $121.46K derived: sum of 2 quarters · filed 2023-03-30 | $140.42K derived: sum of 3 quarters · filed 2023-03-30 | $161.07K 10-K/A · filed 2023-03-30 |
| 2021-09-30 | -$5.76K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $13.20K derived: sum of 2 quarters · filed 2022-11-08 | $33.86K 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $18.97K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $39.62K 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $20.65K 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $108.10K 10-K · filed 2022-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |